Premium
Inhibition of the Rho/ROCK pathway reduces apoptosis during transplantation of embryonic stem cell‐derived neural precursors
Author(s) -
Koyanagi Masaomi,
Takahashi Jun,
Arakawa Yoshiki,
Doi Daisuke,
Fukuda Hitoshi,
Hayashi Hideki,
Narumiya Shuh,
Hashimoto Nobuo
Publication year - 2007
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.21502
Subject(s) - apoptosis , transplantation , microbiology and biotechnology , embryonic stem cell , programmed cell death , caspase , cdc42 , intrinsic apoptosis , biology , chemistry , cell , signal transduction , biochemistry , medicine , gene
Rho‐GTPase has been implicated in the apoptosis of many cell types, including neurons, but the mechanism by which it acts is not fully understood. Here, we investigate the roles of Rho and ROCK in apoptosis during transplantation of embryonic stem cell‐derived neural precursor cells. We find that dissociation of neural precursors activates Rho and induces apoptosis. Treatment with the Rho inhibitor C3 exoenzyme and/or the ROCK inhibitor Y‐27632 decreases the amount of dissociation‐induced apoptosis (anoikis) by 20–30%. Membrane blebbing, which is an early morphological sign of apoptosis; cleavage of caspase‐3; and release of cytochrome c from the mitochondria are also reduced by ROCK inhibition. These results suggest that dissociation of neural precursor cells elicits an intrinsic pathway of cell death that is at least partially mediated through the Rho/ROCK pathway. Moreover, in an animal transplantation model, inhibition of Rho and/or ROCK suppresses acute apoptosis of grafted cells. After transplantation, tumor necrosis factor‐α and pro‐nerve growth factor are strongly expressed around the graft. ROCK inhibition also suppresses apoptosis enhanced by these inflammatory cytokines. Taken together, these results indicate that inhibition of Rho/ROCK signaling may improve survival of grafted cells in cell replacement therapy. © 2007 Wiley‐Liss, Inc.